Detail akcie Tandem Diabetes Rg online

Business Summary: Tandem Diabetes Care, Inc. is a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems. Its pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Its t:slim X2 and Tandem Mobi pumps can be used with a variety of infusion sets to offer patients choice in how and where their pump is worn. In addition, they are software updatable from a personal computer and compatible with its Web-based data management application. Both pumps feature its Control-IQ advanced hybrid closed loop technology, with an automated insulin delivery (AID) feature designed to help increase a user's time in the targeted glycemic range. There are two primary therapies used by people with insulin-dependent diabetes, Multiple Daily Injection (MDI) and insulin pumps. As part of its AID systems, it offers pump integration with multiple CGM sensors.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Tandem Diabetes Care Inc revenues increased 10% to $724.4M. Net loss increased from $96.8M to $204.1M. Revenues reflect Supplies and other-International segment increase of 22% to $146.2M, Supplies and other - Domestic segment increase of 11% to $254.1M. Higher net loss reflects Acquired in-process research and develop increase from $0K to $75.2M (expense), Other Selling.